J Korean Med Sci.  2004 Aug;19(4):547-553. 10.3346/jkms.2004.19.4.547.

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane

• Ahn JH
• Kim SB
• Kim TW
• Ahn SH
• Kim SM
• Park JM
• Lee JS
• Kang YK
• Kim WK

• KMID: 2157684
• DOI: http://doi.org/10.3346/jkms.2004.19.4.547

Abstract

We have evaluated the efficacy and safety of the combination of capecitabine and vinorelbine in metastatic breast cancer (MBC) patients previously treated with anthracycline-and taxane-containing regimens. Between April 2000 and September 2002, 44 female MBC patients received oral capecitabine (1,250 mg/m(2) twice daily on days 114), and intravenous vinorelbine (25 mg/m2 on days 1 and 8) during each 3 weekchemotherapy cycle (median, 5 cycles/patient; total, 235 cycles). One patient achieved a complete response and 21 patients had partial responses, giving an overall response rate of 50% in the intention-to-treat analysis (95% CI, 35.0-65.0%). Median duration of response was 6.0 months (range 1.2-23.0 months). Patients were followed- up for a median of 16 months, with median progression-free survival being 5.3 months, and median overall survival being 17 months. Toxicities included grades III and IV neutropenia in 63 (26.8%) and 4 (1.7%) cycles, respectively, and grades II and III hand-foot syndrome in 12 (5.1%) and 4 (1.7%) cycles, respectively. Other nonhematologic toxicities were minimal and manageable. In conclusion, the combination of capecitabine and vinorelbine was effective and well tolerated in MBC patients even after treatment with anthracyclines and taxanes.

Keyword

Breast Neoplasms; Drug Therapy; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Vinorelbine

MeSH Terms

Adult
Aged
Anthracyclines/*therapeutic use
Antineoplastic Agents/*therapeutic use/toxicity
Breast Neoplasms/*drug therapy/*pathology
Deoxycytidine/*analogs & derivatives/*therapeutic use/toxicity
Drug Therapy, Combination
Female
Humans
Middle Aged
Neoplasm Metastasis
Prodrugs
Retrospective Studies
Survival Rate
Taxoids/*therapeutic use
Treatment Outcome
Vinblastine/*analogs & derivatives/*therapeutic use/toxicity

Figure

• 

  Fig. 1 Response duration for 22 responders (median, 6.0 months; range, 1.2-23.0 months).

• 

  Fig. 2 Progression-free survival for all patients (median, 5.3 months; range, 1.8-30.0 months).

Reference

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001. 51:15–36.

2. Tormey C. Adriamycin (NSC 123-127) in breast cancer. An overview of studies. Cancer Chemother Rep. 1975. 3:319–327.

3. Stewart DJ, Evans WK, Shepherd FA, Wilson KS, Pritchard KI, Trudeau ME, Wilson JJ, Martz K. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: Superiority of doxorubicin. J Clin Oncol. 1997. 15:1897–1905.

4. Perez EA. Paclitaxel in breast cancer. Oncologist. 1998. 3:373–389.

5. Budman DR. Vinorelbine (Navelbine): A third-generation vinca alkaloid. Cancer Invest. 1997. 15:475–490.

6. Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: An overview. Cancer Treat Rev. 1996. 22:127–142.

7. Smith GA. Current status of vinorelbine for breast cancer. Oncology. 1995. 9:767–773.

8. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Romero Acuna L. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994. 12:336–341.

9. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993. 11:1245–1252.

10. Twelves CJ, Dobbs NA, Curnow A, Coleman RE, Stewart AL, Tyrrell CJ, Canney P, Rubens RD. A phase II multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer. 1994. 70:990–993.

11. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995. 13:2722–2730.

12. Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P, Marty M. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: Results of a phase II study using a sequential group method. J Clin Oncol. 1996. 14:3097–3104.

13. Zambetti M, Demicheli R, De Candis D, Antonelli G, Giacobone A, Terenziani M, Laffranchi A, Garbagnati F, Biasi S, Bonadonna G. Five day infusion fluorouracil plus vinorelbine iv in metastatic pretreated breast cancer patients. Breast Cancer Res Treat. 1997. 44:255–260.

14. Froudarakis ME, Catimel G, Guastalla JP, Rebattu P, Clavel M. Phase II trial of navelbine and fluorouracil as second-line chemotherapy in metastatic breast carcinoma. Oncology. 1998. 55:87–88.

15. Cany L, Toulouse C, Ravaud A, Durand M, Mauriac L. Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy: A retrospective study of 63 cases. Eur J Cancer. 1996. 32A:370–371.

16. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J. Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998. 16:2977–2985.

17. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol. 1998. 16:1795–1802.

18. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999. 17:485–493.

19. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998. 4:1013–1019.

20. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine (Xeloda) or 5'-deoxy-5-fluorouridine (Furtulon) by cyclophosphamide in mammary tumor models. Int J Cancer. 1999. 83:127–134.

21. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs. 2000. 18:343–354.

22. Tonkin K, Scarfe AG, Koski S, Bodnar D, Smylie M, Au HJ, Nabholtz JM, Mackey JR. Preliminary Results of a Phase I/II Study of Weekly Docetaxel (Taxotere®) Combined with Intermittent Capecitabine (Xeloda®) for Patients with Anthracycline Pre-Treated Metastatic Breast Cancer. Proc Am Soc Clin Oncol. 2001. 20:(Abstr 2016).

23. Maher JF, Villalona-Calero MA. Taxanes and capecitabine in combination: rationale and clinical results. Clin Breast Cancer. 2002. 2:287–293.

24. Meza LA, Amin B, Horsey M, Petralia SA, Szatrowski TP, Gradishar WJ. A Phase II Study of Capecitabine in Combination with Paclitaxel as First or Second Line Therapy in Patients with Metastatic Breast Cancer (MBC). Proc Am Soc Clin Oncol. 2001. 20:(Abstr 2029).

25. Sawada N, Fujimoto-Ouchi K, Ishikawa T. Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res. 2002. 21:(Abstr 5388).

26. Stuart N, Bishop JL, Johnson SRD, Smith IE, O'Brien M, Whipp EC, Gregory K, Laing RW. Vinorelbine and capecitabine (VX) for advanced breast cancer a phase II study showing good activity and potential for further development. Proc Am Soc Clin Oncol. 2003. 22:(Abstr 183).

27. Nole F, Catania C, Mandala M, Munzone E, Rocca A, Zampino G, Minchella I, Noberasco C, Colleoni M, Marrocco E, Lambiase A, Goldhirsch A. Phase I Study of Vinorelbine (V) and Capecitabine (C) in Advanced Breast Cancer (ABC). Proc Am Soc Clin Oncol. 2000. 19:(Abstr 428).

28. Welt A, Borquez D, Oberhoff C, Tewes M, Flmer F, Mohrbacher R, Vanhoefer U, Seeber S. Phase I study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Proc Am Soc Clin Oncol. 2001. 20:(Abstr 1979).

29. Lorusso V, Crucitta E, Silvestris N, Guida M, Misino A, Latorre A, De Lena M. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer. Clin Breast Cancer. 2003. 4:138–141.

30. Ahn JH, Kim SB, Ahn SH, Lee JS, Kim WK. Phase II study of a combination chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxane: Final Results. Proc Am Soc Clin Oncol. 2003. 22:(Abstr 2030).

31. NCI common toxicity criteria. http//ctep.info.nih.gov/CTC3/ctc.htm.

32. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002. 20:2812–2823.

33. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol. 2001. 19:1707–1715.

34. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter phase III trial. J Clin Oncol. 2002. 15:3114–3121.